SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Cuttano Roberto)
 

Search: WFRF:(Cuttano Roberto) > (2015) > Sulindac metabolite...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Bravi, Luca (author)

Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice

  • Article/chapterEnglish2015

Publisher, publication year, extent ...

  • 2015-06-24
  • Proceedings of the National Academy of Sciences,2015
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-259652
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-259652URI
  • https://doi.org/10.1073/pnas.1501352112DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • This study was supported by grants (to E.D.) from TELETHON-GGP14149, Associazione Italiana per la Ricerca sul Cancro (AIRC) (AIRC IG 14471), "Special Program Molecular Clinical Oncology 5x1000" to AIRC-Gruppo Italiano Malattie Mieloproliferative, Fondazione Cassa di Risparmio delle Provincie Lombarde (CARIPLO) Contract 2012-0678, the European Community (Wnt for Brain Contract 268870; Innovative Training Networks Vessel 317250, Endostem-Health-2009-241440), and Fondazione CARIPLO Contract 2014-1038 (to N.R.). R.C. was supported by the FIRC fellowship 16617. Part of this work was funded by the European consortium European Research Area Network NEURON (to E.T.-L.).Dejana E and Lampugnani MG share the last authorship and corresponding.
  • Cerebral cavernous malformation (CCM) is a disease of the central nervous system causing hemorrhage-prone multiple lumen vascular malformations and very severe neurological consequences. At present, the only recommended treatment of CCM is surgical. Because surgery is often not applicable, pharmacological treatment would be highly desirable. We describe here a murine model of the disease that develops after endothelial-cell-selective ablation of the CCM3 gene. We report an early, cell-autonomous, Wnt-receptor-independent stimulation of beta-catenin transcription activity in CCM3-deficient endothelial cells both in vitro and in vivo and a triggering of a beta-catenin-driven transcription program that leads to endothelial-tomesenchymal transition. TGF-beta/BMP signaling is then required for the progression of the disease. We also found that the anti-inflammatory drugs sulindac sulfide and sulindac sulfone, which attenuate beta-catenin transcription activity, reduce vascular malformations in endothelial CCM3-deficient mice. This study opens previously unidentified perspectives for an effective pharmacological therapy of intracranial vascular cavernomas.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Rudini, Noemi (author)
  • Cuttano, Roberto (author)
  • Giampietro, Costanza (author)
  • Maddaluno, Luigi (author)
  • Ferrarini, Luca (author)
  • Adams, Ralf H. (author)
  • Corada, Monica (author)
  • Boulday, Gwenola (author)
  • Tournier-Lasserve, Elizabeth (author)
  • Dejana, ElisabettaUppsala universitet,Vaskulärbiologi(Swepub:uu)elide443 (author)
  • Lampugnani, Maria Grazia (author)
  • Uppsala universitetVaskulärbiologi (creator_code:org_t)

Related titles

  • In:Proceedings of the National Academy of Sciences of the United States of America: Proceedings of the National Academy of Sciences112:27, s. 8421-84260027-84241091-6490

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view